🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

LCTX LCTX

Company Profile ↓
$1.14
+17.53% 1Y
P/E-4.07
52W High$1.96
52W Low$0.95
EPS (TTM)$-0.28

Company Overview

LCTX (LCTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 13.5% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $14.56M (+53.2% YoY); net profit $-63.53M.
  • Trailing 12 Months Year-on-year growth — revenue +53.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.48%
1 Year:53.24%

Stock Price Performance

1 Year:+17.53%
6 Months:-35.23%
3 Months:-21.92%
1 Month:-13.64%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 19% of range
$0.95 $1.96
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)47.66 · Neutral
Price Performance
1M-13.64%
3M-21.92%
6M-35.23%
1Y+17.53%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 13.5% over 5 years.

CONS

  • Trading 41.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.07
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
13.48%
Profit 5Y
-
Revenue (YoY)
53.24%
Earnings (YoY)
-

Profitability & Returns

ROCE
-36.18%
ROE
-142.61%
ROA
-56.43%
Profit Margin
-
Op Margin
-
Gross Margin
56.84%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.28

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$109.53M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
4.93%
Chg in Prom Hold
-
FII / Inst Holding
48.01%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$14.56M
EBITDA
-
Free Cash Flow
$-19.44M
Operating Cash Flow
$-18.92M
Shares Outstanding
-
Gross Margin
56.84%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------------------------3.00M-2.39M3.23M1.25M-1.44M1.41M3.78M1.50M2.77M3.68M1.73M
Gross Profit -1.85M1.17M1.44M-333.00K376.00K1.64M-592.00K2.44M947.00K-860.00K672.00K453.00K-420.00K311.00K469.00K-279.00K387.00K1.28M-5.06M4.34M2.76M-2.27M3.10M1.08M--------
Operating Income -21.71M-23.76M-14.40M-9.55M-11.25M-11.26M-8.56M-9.51M-9.56M-12.19M-9.14M-10.36M-10.11M-12.76M-10.82M-8.42M-6.87M-7.44M-6.40M-6.72M-5.88M-7.05M-7.08M-6.84M-28.24M-6.40M-4.23M-5.25M-6.64M-6.64M-5.02M-6.71M-6.36M-6.66M-5.87M-3.84M-6.50M-19.78M-3.79M-7.59M
Net Income -13.51M-17.11M24.55M31.20M-4.95M49.29M-11.65M14.32M-71.93M-63.55M-4.21M66.72M-44.95M39.31M-30.03M-16.50M-4.48M-8.40M-6.52M-7.76M2.03M-1.42M-4.79M-7.82M-28.99M-7.09M-6.76M-6.07M-6.35M-4.37M-5.23M-7.11M-4.78M-6.54M-5.76M-3.03M-4.14M-30.46M-29.78M-4.81M
Diluted EPS --0.190.260.30-0.46-0.110.12--0.50-0.030.53-0.30-0.20-0.11--0.06-0.04-0.05--0.01-0.03-0.05--0.04-0.04-0.04-0.03-0.03-0.03-0.04-0.03-0.04-0.03-0.02-0.02-0.13-0.13-0.03
R&D Expense -13.73M8.94M6.42M-6.49M6.27M6.56M-5.93M6.36M4.88M-4.96M5.24M4.27M-3.34M2.81M3.57M-3.39M2.93M2.81M-2.99M3.30M3.59M-4.18M3.87M3.74M-3.01M2.87M3.17M3.11M3.11M3.27M4.23M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.93M3.71M4.43M3.92M4.43M5.24M7.04M5.92M3.46M4.99M3.52M1.83M4.34M14.70M8.95M9.50M14.56M
Gross Profit -3.68M4.35M3.48M3.64M4.41M5.93M5.57M3.29M4.69M3.10M1.44M2.92M13.97M8.27M--
Operating Income -3.52M-9.85M-18.69M-25.00M-55.99M-50.68M-65.81M-58.97M-38.90M-41.80M-38.88M-26.45M-49.21M-22.52M-24.73M-21.48M-36.62M
Net Income -5.14M-11.18M-16.52M-21.43M-43.88M-36.41M-46.99M33.57M-19.98M-45.99M-11.71M-20.65M-43.02M-26.27M-21.49M-18.61M-63.53M
Diluted EPS ------0.55-0.590.34-0.17-----0.15-0.12-0.09-0.28
R&D Expense -3.18M8.19M13.70M18.12M26.61M37.53M42.60M36.11M24.02M20.95M17.95M12.32M33.91M13.99M15.71M12.47M17.73M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --53.27M45.83M29.75M57.73M74.90M94.66M142.57M173.24M101.66M125.48M107.95M174.54M123.66M101.02M113.22M112.58M
Total Equity -4.35M11.05M38.17M28.65M9.58M14.80M36.46M25.82M117.93M162.64M93.84M112.96M96.20M92.22M73.34M63.42M78.38M44.55M
Cash & Equivalents 12.28K12.19M33.32M22.21M4.35M5.50M29.49M42.23M22.09M36.84M23.59M9.50M32.59M55.74M11.36M35.44M45.79M40.79M
Total Liabilities -------18.21M12.06M8.98M9.41M14.23M12.82M83.65M51.73M39.00M36.21M69.24M
Current Liabilities --2.48M3.15M4.39M6.96M7.07M12.46M8.85M6.88M6.81M6.49M7.77M47.12M18.98M17.96M13.98M11.37M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.26M-7.73M-13.59M-19.68M-29.51M--44.54M-42.33M-30.52M-30.88M-31.95M-19.75M-23.56M1.06M-28.57M-23.09M-18.92M
Investing Cash Flow -46.23K3.20M-1.20M-104.69K-3.67M--7.44M-10.89M-10.22M11.82M16.96M13.04M9.74M-46.16M46.45M-2.31M-13.46M
Financing Cash Flow 16.48M25.77M3.86M1.91M34.26M-64.78M32.78M55.39M5.77M617.00K29.86M36.93M1.63M6.42M35.86M26.95M
Capital Expenditure -61.28K-220.77K-960.28K-400.81K-2.28M-483.00K-1.24M-2.25M-1.33M-556.00K-440.00K-64.00K-340.00K-413.00K-674.00K-565.00K-522.00K
Free Cash Flow -4.32M-7.95M-14.55M-20.08M-31.79M--45.78M-44.57M-31.84M-31.44M-32.39M-19.82M-23.90M646.00K-29.24M-23.66M-19.44M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -99.3%98.2%88.9%82.1%84.0%84.3%94.0%95.1%93.9%88.3%78.9%67.2%95.0%92.5%--
Operating Margin % -182.9%-265.7%-421.4%-638.5%-1,262.7%-966.5%-935.3%-995.6%-1,125.0%-837.9%-1,106.0%-1,448.4%-1,133.6%-153.2%-276.5%-226.1%-251.6%
Net Margin % -267.2%-301.6%-372.5%-547.2%-989.7%-694.4%-667.9%566.8%-577.7%-922.0%-333.1%-1,130.8%-991.0%-178.7%-240.2%-195.9%-436.5%
ROE % -46.6%-29.3%-57.7%-223.5%-296.5%-99.9%-182.0%28.5%-12.3%-49.0%-10.4%-21.5%-46.6%-35.8%-33.9%-23.7%-142.6%
ROCE % --19.4%-43.8%-98.6%-110.3%-74.7%-80.1%-44.1%-23.4%-44.1%-32.7%-26.4%-38.6%-21.5%-29.8%-21.6%-36.2%

Shareholding Pattern

Insiders
4.93%
Institutions
48.01%
Public Float
50.50%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LCTX

Yahoo Finance hu, 30 Jul 2026

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

CARLSBAD, Calif., July 30, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today anno…

Yahoo Finance ue, 14 Jul 2026

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corne…

Yahoo Finance Mon, 13 Jul 2026

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

CARLSBAD, Calif., July 13, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today prov…

Yahoo Finance Mon, 06 Jul 2026

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

CARLSBAD, Calif., July 06, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced tha…

Yahoo Finance hu, 18 Jun 2026

Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage

The updated analyst narrative around Lineage Cell Therapeutics centers on a reaffirmed US$5.50 price target, with recent research focusing on how this level lines up with the company’s current execution profile. Rather than introducing new …

Yahoo Finance hu, 04 Jun 2026

How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets

Lineage Cell Therapeutics is back on investor radar as bullish analysts lift their price target from US$4.50 to US$5.50 per share, pointing to a different view on where the stock could sit if their models play out. These higher targets are …

LCTX — Frequently Asked Questions

What is the current share price of LCTX?

As of 2026-08-05 17:25 PDT, LCTX trades at $1.14 on NASDAQ/NYSE. Its 52-week range is $0.95 to $1.96.

What is the P/E ratio of LCTX?

LCTX trades at a trailing price-to-earnings (P/E) ratio of -4.07.

What is the return on equity (ROE) of LCTX?

LCTX has a return on equity (ROE) of -142.61%. Its return on capital employed (ROCE) is -36.18%.

Is LCTX a good stock to buy?

This page provides a data-driven analysis of LCTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space